Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lupin Limited ( (IN:LUPIN) ) has provided an update.
Lupin Limited has announced updates regarding the transfer of its API R&D Division and Over-the-Counter Consumer Healthcare Business to its wholly owned subsidiaries. The Business Transfer Agreement for the API R&D Division with Lupin Manufacturing Solutions Limited is expected to be executed by June 30, 2025. Similarly, the transfer of the Over-the-Counter Consumer Healthcare Business to LUPINLIFE Consumer Healthcare Limited is also anticipated to be completed by the same date. These strategic moves aim to streamline operations and enhance the company’s focus on core business areas.
More about Lupin Limited
Lupin Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company has a significant presence in the global healthcare market, with a particular emphasis on providing affordable healthcare solutions.
YTD Price Performance: -10.88%
Average Trading Volume: 28,146
Current Market Cap: 962.3B INR
For an in-depth examination of LUPIN stock, go to TipRanks’ Stock Analysis page.